Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 6/20 | 0.58 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.47 |
| ▸ | TK1 | P04183 | 3/20 | 0.46 |
| ▸ | TK2 | O00142 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29760775 | 1.00 | TOP2A (0.58) | TOP2ARNASE1HDAC1TK1TK2 | |
| SCHEMBL4578745 | 1.00 | TOP2A (0.58) | TOP2ARNASE1HDAC1TK1TK2 | |
| SCHEMBL23734352 | 0.92 | TOP2A (0.49) | TOP2ARNASE1HDAC1TK1 | |
| SCHEMBL16704350 | 0.85 | RNASE1 (0.55) | RNASE1TK1TK2 | |
| SCHEMBL1514947 | 0.85 | TOP2A (0.65) | TOP2ARNASE1HDAC1TK1 | |
| SCHEMBL21563908 | 0.85 | TOP2A (0.65) | TOP2ARNASE1HDAC1TK1 | |
| SCHEMBL12570186 | 0.85 | TOP2A (0.65) | TOP2ARNASE1HDAC1TK1 | |
| SCHEMBL12762676 | 0.85 | TOP2A (0.65) | TOP2ARNASE1HDAC1TK1 | |
| SCHEMBL26231578 | 0.85 | TOP2A (0.65) | TOP2ARNASE1HDAC1TK1 | |
| SCHEMBL25752670 | 0.85 | RNASE1 (0.59) | RNASE1TK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158425-A1 | MODIFIED ADENINES | NUCLERA LTD (GB) | 2024-05-16 | — | — | US | disclosed |
| EP-0649429-B1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2008-08-27 | — | — | EP | disclosed |
| US-6214551-B1 | CONTACTING TEST SOLUTION CONTAINING NUCLEIC ACID WITH COMPOUND CONTAINING NUCLEOSIDE SEQUENCE WHEREIN NUCLEOSIDES ARE COVALENTLY BOUND THROUGH LINKING GROUP HAVING ADJACENT NITROGEN ATOMS FOR ASSAYING SEQUENCE-SPECIFIC NUCLEIC ACID | ISIS PHARMACEUTICALS, INC. | 2001-04-10 | — | — | US | disclosed |
| US-6025482-A | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5969118-A | NUCLEOSIDES AND OLIGONUCLEOTIDES WITH INCREASED NUCLEASE RESISTANCE AND CELLULAR UPTAKE; FOR DIAGNOSIS AND ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5808023-A | Modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5792844-A | MIMIC AND/OR MODULATE THE ACTIVITY OF WILD-TYPE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5777092-A | Heteroatomic oligonucleoside linkages | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5623070-A | Heteroatomic oligonucleoside linkages | ISIS PHARMACEUTICALS, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| US-5618704-A | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling | ISIS PHARMACUETICALS, INC. (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0649429-A4 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES. | ISIS PHARMACEUTICALS INC (US) | 1996-04-10 | — | — | EP | disclosed |
| US-5489677-A | NUCLEASE RESISTANT OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0649429-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5386023-A | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling | ISIS PHARMACEUTICALS (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1994022894-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS AND PREPARATION THEREOF THROUGH RADICAL COUPLING | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022893-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022883-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDES AND THEIR PREPARATION | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022454-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT OXYGEN AND NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994000467-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158425-A1 | MODIFIED ADENINES | RNGTT, ADAR, MRM1 | TOP2A 334/4885RNASE1 83/4885HDAC1 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.